RPS6KB2 and chronic myelogenous leukemia, BCR-ABL1 positive: In line with our observations in human CML patients, metabolomic analysis of these mice indicated that IM treatment tended to decrease dipeptide levels in CML-KLS+ cells (Fig. 6b).